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Tumor Cavitation During Therapy with Antiangiogenesis
Agents in Patients with Lung Cancer
Edith M. Marom, MD,* Carlos H. Martinez, MD,† Mylene T. Truong, MD,* Xiudong Lei, PhD,‡
Bradley S. Sabloff, MD,* Reginald F. Munden, MD,* Gregory W. Gladish, MD,* Roy S. Herbst, MD,§
Rodolfo C. Morice, MD,† David J. Stewart, MD,§ Carlos A. Jimenez, MD,†
George R. Blumenschein, Jr., MD,§ and Amir Onn, MD†
Purpose: Treatment of lung cancer patients with antiangiogenesis
agents is a new promising paradigm. Tumor cavitation is frequently
noted in these patients, but the clinical significance of this finding
has not been fully determined. Our purposes were to evaluate the
frequency, imaging characteristics, and clinical outcome of patients
receiving antiangiogenesis agents who develop tumor cavitation,
and correlate these findings with therapy related adverse events,
especially hemoptysis.
Methods: Retrospective analysis of lung cancer patients treated
with antiangiogenesis agents in MD Anderson Cancer Center be-
tween June 1998 and June 2005. Clinical data were retrieved from
medical records, and chest imaging findings were documented.
Results: One hundred and twenty-four patients were treated in 10
different trials. All patients had advanced lung cancer and failed
previous chemotherapy. Seventeen patients developed tumor cavi-
tation during the trial (14%; median time to event, 1.8 months;
range, 0.7–6.2 months), 16 patients (13%) had preexisting cavitary
tumors, and 91 (73%) did not develop cavitation. Cavity formation
was more common with squamous cell histology (p 0.04) but was
not associated with hemoptysis (p  0.12), tumor location (central
versus peripheral), imaging characteristics, progression-free survival
(p  0.56), or overall survival (p  0.33). Hemoptysis was noted in
five patients (median time to event, 1.3 months; range, 0.8–2.9
months). One of five patients with hemoptysis was fatal in a cavitary
squamous cell tumor. Additional adverse events were hypertension,
rash, and proteinuria, none associated with cavitation.
Conclusion: Development of tumor cavitation is not rare in lung
cancer patients treated with antiangiogenesis agents, but the clinical
implications are minimal in most cases.
Key Words: Non-small cell lung cancer, Antiangiogenesis, Cavi-
tation, Hemoptysis, CT.
(J Thorac Oncol. 2008;3: 351–357)
The addition of the vascular endothelial growth factor(VEGF) inhibitor bevacizumab to platinum-based chemo-
therapy provides a survival advantage with tolerable toxicity
in patients with nonsquamous non-small cell lung cancer
(NSCLC).1 However, in an earlier phase II trial looking at 67
patients who received bevacizumab in addition to platinum-
based chemotherapy, 6 patients experienced life-threatening
pulmonary hemorrhage, 4 of whom died.2 Analysis of risk
factors of these cases of pulmonary hemorrhage found squa-
mous-cell histology as the only statistically significant risk
factor in that study, though tumors tended to be central and
cavitary.2 Since then, many trials using antiangiogenesis
agents have excluded patients with squamous-cell histology,
and some trials have excluded patients with centrally located
tumors, who may otherwise benefit from this targeted ther-
apy. Clinicians are often reluctant to continue therapy with
these novel agents in nonsquamous patients with centrally
located tumors who cavitate during treatment.
The purpose of our study was to characterize imaging
findings that occur in lung tumors in patients with NSCLC
undergoing treatment with antiangiogenesis agents and to
assess if there are any imaging characteristics that predict
cavitation or adverse events such as major hemoptysis.
METHODS
Patients
All patients with histologically proven NSCLC who were
enrolled into any antiangiogenesis agent clinical trial at the
University of Texas MD Anderson Cancer Center (MDACC)
between June 1998 and June 2005 were considered for our
study. The clinical trials were identified from a dedicated data-
base (Protocol Data Management System) maintained in the
Department of Thoracic, Head and Neck Medical Oncology.
During this period, 10 different clinical trials were
developed, using seven different agents defined as antiangio-
genic at the time of the trial: Bevacizumab (Avastin), a
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monoclonal antibody to VEGF; ZD6474 (vandetanib, Zac-
tima), a tyrosine kinase inhibitor (TKI) of the epidermal
growth factor and VEGF receptors; BAY43-9006 (sorafenib,
Nexavar), a multitarget TKI; Erlotinib (Tarceva), an epider-
mal growth factor-receptor TKI; AMG-706, a multitarget
TKI; Exherin, an N-cadherin inhibitor; and squalamine (Evi-
zon), a VEGF inhibitor extracted from shark cartilage. Al-
though minor differences existed in the inclusion criteria
between trials, all were restricted to patients with proven
stage IIIB (with pleural effusion) or IV NSCLC, the majority
with disease relapsing after a platinum-based chemotherapy,
and a Karnofsky performance status 70%, or an Eastern
Cooperative Oncology Group performance status of 0 to 1,
with stable hepatic, hematologic, and renal function. The
majority of the trials planned after 2003 did not include
patients with squamous-cell histology. All patients were
treated at a single center (MDACC). To be included in our
study, all patients had to have received at least one dose of an
antiangiogenesis agent, and had to have complete clinical
data including a follow-up chest CT performed at least 4
weeks after the first dose of these agents.
Our institutional review board approved our retrospec-
tive study, with a waiver of informed consent, and this study
was in compliance with Health Insurance Portability and
Accountability Act regulations. No external financing was
obtained for this study.
Clinical Data
Clinical data were retrieved from the Protocol Data
Management System, and confirmed with data from medical
charts. Information obtained included: patients’ age, gender,
stage of disease, histology of tumor, antiangiogenesis agent
administered, inclusion and withdrawal date, adverse events,
oncologic clinical response, comorbid conditions, and smok-
ing history. Information about drug toxicity was based on the
original investigator report and was graded according to the
National Cancer Institute Common Toxicity Criteria version
2.3 Documentation of the oncologic clinical response was
based on the principal investigator’s definition using the
criteria of the original research protocols. Briefly, all studies
used similar response criteria, which were classified as com-
plete response, partial response, stable disease, and progres-
sive diseases (according the RECIST criteria4: complete
response was defined as complete disappearance of all radio-
graphically detectable malignant disease. Partial response was
defined as a 30% decrease in the sum of the longest diameter of
target lesions. Progressive disease was defined as a significant
increase (i.e.,20%) in the size of lesions present at the start of
treatment or after a response, or the appearance of new meta-
static lesions not present at the start of treatment. Stable disease
was defined as small changes that do not meet the above criteria).
Progression-free survival was defined as the months between
the start of therapy and the development of PD, and survival
time as the time difference, in months, between the initial
dose of the antiangiogenesis agent and death of the patient.
Radiologic Evaluation
All patients included in the study had a chest CT in
MDACC within a month before starting the antiangiogenesis
agent. CT examinations were performed on a variety of helical
scanners. Section thickness used was 10 mm (n  12), 8 mm
(n  3), 7.5 mm (n  6), 7 mm (n  13), 5 mm (n  4), 3.75
mm (n  44), 3 mm (n  1), 2.5 mm (n  39), and 1.25 mm
(n  2). Intravenous contrast enhancement was used in 118
patients (95%). Follow-up scans were performed every 6 weeks
as part of the regular follow-up for the research protocol with the
antiangiogenesis agent. All chest CT studies available from the
month before the patient was started on the antiangiogenesis
agent to the time of development of cavitation, death, or January
24, 2007 (whatever occurred first) were evaluated to detect the
development of cavitation in the pulmonary tumor.
CT scans were retrospectively reviewed by two expe-
rienced thoracic radiologists (E.M.M., M.T.T., 10 years ex-
perience each) using soft copy (n 94) or hard copy (n 30)
and differences were resolved by consensus. At the time of
interpretation, the interpreting physicians were informed that
the patient had NSCLC and was receiving antiangiogenesis
agents, but were blinded to any other clinical data. Imaging
characteristics of the dominant pulmonary lesions, primary or
metastatic, were recorded. These characteristics included di-
ameter of the dominant lung tumor, type of contour (spicu-
lated, round, lobular), type of margins (poorly or well demar-
cated), attenuation of the nodule (solid, ground-glass [hazy
opacity not associated with obscuration of underlying ves-
sels], or mixed [a combination of solid and ground-glass]),
presence of cavitation (defined as the presence of air in the
tumor at the time of diagnosis, before biopsy or treatment),
location of the tumor as its relationship to the airway order
(the largest airway the tumor involves), artery order (the
largest artery the tumor involves), and lobe involved. The
presence of hilar and mediastinal lymphadenopathy, de-
fined as short axis diameter larger than 1 cm, was also
recorded.
Statistical Analysis
Descriptive statistics were used to summarize the pa-
tients’ demographic characteristics, treatment history, histol-
ogy, comorbidities, and adverse events. 2 Test was used to
examine the association of two categorical variables (for
example, development of cavity versus tumor location).
When the cells had expected counts less than 5, p values from
Fisher exact test were cited. Log-rank test was used to
compare overall survival or progression-free survival in dif-
ferent groups by assuming Cox proportional hazard model.
Kaplan-Meier plots were shown to illustrate the difference in
survival times. Logistic regression model was used when
testing the association of a binary outcome (developing cav-
ity, hemoptysis) versus continuous variables (for example,
tumor size). A p value less than 0.05 was defined as signif-
icant. All the statistical analyses were performed using SAS
Version 9.1 (SAS Institute, Cary, NC).
RESULTS
Patients
There were 124 patients enrolled in 10 antiangiogenesis
agent protocols (Table 1): 62 men and 62 women, mean age
61 years (range, 29–85 years), who received at least one
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cycle of the agent under evaluation, and had at least one
clinical and imaging follow-up after inclusion in the protocol.
Sixteen were found to have tumor cavitation before initiation
of antiangiogenesis agent and were excluded from those
statistical analyses assessing the significance of developing a
new cavity during treatment.
Clinical Data
The majority of patients had stage IV disease (n 109,
88%). The most frequent cell type was adenocarcinoma (n 
75, 61%). Adenocarcinoma with bronchioloalveolar features
were identified in 21 additional patients (17%) and were
added to the adenocarcinoma group for statistical calculations
(Table 2). Squamous-cell histology was present in 17 patients
(14%). Large-cell carcinoma (n  3) and poorly differenti-
ated NSCLC (n  8) were grouped as “other.”
Comorbid conditions were present in 87 patients
(70%), and included systemic hypertension (n  45, 36%),
hyperlipidemia (n  23, 19%), coronary artery disease (n 
14, 11%), asthma (n 6, 5%), diabetes mellitus (n 6, 5%),
atrial fibrillation (n  5, 4%), thyroid disease (n  5, 5%),
chronic obstructive pulmonary disease (n  5, 4%), arthritis
(n  4, 3%), peptic ulcer (n  2, 2%), cerebral vascular
accident (n  2, 2%), and congestive heart failure (n  2,
2%). Previous radiation therapy was given to 37 (30%)
patients. Smoking history and adverse events on study are
listed in Table 2.
Radiologic Evaluation with Statistical
Correlation
Cavitation before treatment with an antiangiogenesis
agent was seen in 16 (13%) patients. Cavitation developed in
17 patients (14% of the entire group, and 16% excluding
patients with preexisting cavity), and 91 patients never de-
veloped a cavitation (Table 2). Cavitation developed in 8 of
the 10 trials (Table 1, Figure 1). The median time from the
beginning of therapy to the development of cavitation was 1.8
months (range, 0.7–6.2 months). Imaging characteristics are
described in Table 3.
Cavity formation was seen more frequently in tumors
of squamous-cell histology (p 0.04) and in current smokers
(p 0.02) (Table 2), but was not associated with gender (p
0.67), tumor stage (p  0.25), previous radiation therapy
(p  0.71), any comorbidity (p  0.26), or any other
TABLE 1. Clinical Trials with Antiangiogenesis Agentsa
Clinical Trial
Patients
Included
Developed
Cavitation (%)b
No
Cavitation
Preexisting
Cavitation
Squamous
Included
Bevacizumab  carboplatin and paclitaxel 10 2 (22) 7 1 Yes
Bevacizumab  erlotinib 29 4 (15) 22 3 Yes
ZD6474  docetaxel 17 3 (20) 12 2 Yes
BAY43-9006 23 4 (19) 17 2 No
Erlotinib 6 1 (20) 4 1 No
ZD6474 8 1 (17) 5 2 Yes
Exherin 2 1 (100) 0 1 Yes
Bevacizumab  erlotinib 2 10 2 0 No
AMG-706  carboplatin and paclitaxel 4 0 4 0 No
Squalamine  carboplatin and paclitaxel 23 1 (5) 18 4 Yes
Total number of cases 124 17 91 16
a Table includes all agents defined as antiangiogenic at the time of the clinical trial.
b The percent of cavitations developed on therapy compared with all tumors at study initiation, excluding those with preexisting
cavitation.
TABLE 2. Patient Baseline and Demographic Characteristics
No
Cavitation
n (%)
Cavitation
n (%)
Preexisting
Cavity
n (%)
Gender
Male 48 (53) 8 (47) 6 (37.5)
Female 43 (47) 9 (53) 10 (62.5)
Tumor stage
IIIB 11 (12) 4 (24) 0
IV 80 (88) 13 (76) 16 (100)
Tumor histology
Adenocarcinoma 74 (81) 10 (59) 12 (75)
Squamous cell ca 10 (11) 6 (35) 1 (6)
Other 7 (8) 1 (6) 3 (19)
Prior radiation therapy 28 (31) 6 (35) 3 (19)
Smoking history
Never 20 (22) 5 (29) 6 (37)
Current 9 (10) 6 (35) 1 (6)
Past-quit 1 yr 18 (20) 3 (18) 3 (19)
Past-quit 1 yr 43 (47) 3 (18) 5 (31)
Unknown 1 (1) 0 1 (6)
Adverse events
Hypertension 20 (22) 2 (12) 3 (19)
Skin rash 18 (20) 3 (18) 3 (19)
Proteinuria 11 (12) 3 (18) 0
Hemoptysis 2 (2) 2 (12) 1 (6)
Grade 3 and 1 5 and 1 1
Gastrointestinal
bleeding
0 0 0
Deep vein thrombosis or
pulmonary embolus
0 0 0
Journal of Thoracic Oncology • Volume 3, Number 4, April 2008 Tumor Cavitation During Antiangiogenesis Therapy
Copyright © 2008 by the International Association for the Study of Lung Cancer 353
complication related to the antiangiogenesis agent therapy:
hemoptysis (p  0.12), proteinuria (p  0.27), hypertension
(p  0.67), or rash (p  1.0).
The development of a cavity was not associated with
tumor location. Specifically, cavity development was not
associated with lobe involved by tumor (p  0.85), with
involvement of central airways (main bronchus and lobar
bronchi) versus peripheral airways (segmental and subseg-
mental airways) (p  0.85), nor with involvement of central
pulmonary arteries (right or left pulmonary artery and lobar
pulmonary arteries) versus peripheral pulmonary arteries
(segmental and subsegmental arteries) (p  0.91). Imaging
characteristics that were not associated with the development
of a cavity included tumor contour (p  0.83), margin
characteristics (p  1.0), or density (p  0.66).
Oncologic Results, Hemoptysis, and Statistical
Evaluation
During the treatment with antiangiogenesis agents the
oncologic response was similar in frequency between the
tumor cavity groups (Table 4) (p  0.27). Among patients
FIGURE 1. Seventy-one-year old man with squamous cell
lung cancer. A, Coronal chest CT while patient had progres-
sive disease under platinum-based chemotherapy shows a
5.2 cm left upper lobe mass. The mass (M) involved the left
pulmonary artery (straight arrow), left superior pulmonary
vein (curved arrow), the left main bronchus (B) as well as
the left subclavian artery (not shown). A-Transverse aorta. B,
Coronal chest CT 5 weeks following treatment with BAY43-
9006 (sorafenib, a multitarget tyrosine kinase inhibitor).
There has been interval cavitation of the mass. The patient
died of massive hemoptysis 2 months after initiation of
BAY43-9006, 1 month after this chest CT.
TABLE 3. Imaging Findings
Imaging
Characteristic
No Cavitation
n (%)
Cavitation
n (%)
Preexisting Cavity
n (%)
Airwaya
Central 34 (38) 6 (35) 5 (31)
Peripheral 56 (62) 11 (65) 11 (69)
Pulmonary arteriesb
Central 33 (37) 6 (35) 6 (37.5)
Peripheral 57 (63) 11 (65) 10 (62.5)
Contourc
Spiculated 14 (16) 3 (18) 0
Round 33 (37) 5 (29) 6 (37.5)
Lobular 42 (47) 9 (53) 10 (62.5)
Marginc
Well-marginated 66 (74) 13 (76) 9 (56)
Poorly-marginated 23 (26) 4 (24) 7 (44)
Density
Ground glass 0 0 0
Soft tissue 82 (91) 15 (88) 9 (56)
Mixed 8 (9) 2 (12) 7 (44)
Imaging data is missing from one noncavitary lesion because extensive radiation
changes precluded accurate assessment.
a Central airway main bronchus and lobar bronchus; Peripheral segmental and
subsegmental bronchi.
b Central pulmonary artery  left or right pulmonary artery and lobar arteries;
Peripheral  segmental and subsegmental pulmonary arteries.
c Morphologic data missing from two cases without cavitation due to extensive
radiation changes or lymphangitic spread precluding contour evaluation.
TABLE 4. Oncologic Results
Oncologic Results
No
Cavitation
n (%)
Cavitation
n (%)
Preexisting
Cavity
n (%)
Response
Complete  partial 1 (1) 1 (6) 1 (6)
Stable 44 (48) 8 (47) 5 (31)
Progression 46 (51) 8 (47) 10 (63)
Overall survival (median, mo) 13 11 9
Progression-free survival
(median, mo)
4 5 5
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who did not develop cavitation, 46 (51%) experienced dis-
ease progression and all died. Among patients who developed
cavitation, 8 (47%) experienced disease progression and all
died. Among patients who had a preexisting cavitation, 10
(63%) experienced disease progression and 9 (90%) died.
Median follow-up, calculated as the median observation time
among all patients, was 12 months (range, 1–53 months).
Median time to disease progression was 4 months among
patients without cavitation, 5 for patients who had preexisting
cavitation, and 5 for patients who developed cavitation on
therapy, respectively. Median time to death was 13 months
among patients without cavitation, 9 months for patients with
preexisting cavitation, and 11 months for patients who devel-
oped cavitation on therapy. Progression-free survival and
overall survival were not affected by the development of a
new cavity during antiangiogenesis agent treatment (p 0.56
and 0.33, respectively) (Figure 2), nor were they affected by
the presence of a cavity before antiangiogenesis agent treat-
ment (p  0.76 and 0.57).
Five patients developed hemoptysis, 2 in the group with
no cavity, 2 who developed a cavity, and 1 in the group with
a preexisting cavity. Hemoptysis developed from 0.8 to 2.9
months after initiation of antiangiogenesis agent treatment
(median, 1.3 months). Three of the hemoptysis cases were
1
0.8
0.6
0.4
0.2
0 Logrank p=0.5575
No  Cavity
Yes  Cavity
0                                10                  20                                30                                40    
No. of Subjects        Event       Censored   Median   Survival  (95% CL)
      No Cavity             91                87% (79)     13% (12)      4.00      (2.00    5.00) 
Yes Cavity           17                94% (16)       6% (1)        5.00      (3.00     7.00)
No  Cavity
Yes  Cavity
1
0.8
0.6
0.4
0.2
0 Logrank p=0.3270
No. of Subjects        Event       Censored   Median   Survival  (95% CL)
    No Cavity             91                87% (79)     13% (12)     13.00     (11.00   17.00)
Yes Cavity           17                94% (16)       6% (1)       11.00      (6.00    20.00)
0                        10             20                        30                        40                        50 FIGURE 2. Progression-free survival
(A) and overall survival (B) as as-
sessed by cavity formation (exclud-
ing those patients with preexisting
cavities). Progfree—progression-free
survival.
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treated with BAY43-9006, one with bevacizumab plus erlo-
tinib and one with squalamine with carboplatin and pacli-
taxel. Only one (20%) of the hemoptysis patients had squa-
mous histology, and developed fatal hemoptysis, despite
initiation of palliative radiation therapy. The rest were ade-
nocarcinoma, one with grade 3 hemoptysis from the noncavi-
tary group and the other 3 had grade 1 hemoptysis (Table 2).
Hemoptysis was associated with tumor size (p  0.04). The
mean tumor size of patients with hemoptysis was 6.7 cm
(range, 5.2–8 cm) when compared with 3.9 cm (range,
0.2–16 cm) in patients without hemoptysis. Hemoptysis was
not associated with pretreatment cavity or cavity formation
during treatment (p  0.12), cavity size (p  0.6), cavity/
mass ratio (p  0.79), histology (p  0.73), prior radiation
therapy (p  1.0), nor central tumor (p  0.65). More
detailed comparison of airway and pulmonary artery associ-
ation with tumor showed that hemoptysis was more com-
monly seen with tumors that involved a segmental airway
(p  0.02) or artery (p  0.02), rather than a main bronchus
or artery.
DISCUSSION
Our analysis of 124 lung cancer patients who received
antiangiogenesis agents showed that 17 patients developed
cavitary lesions (16% excluding those with preexisting cav-
ities). Tumors with squamous-cell histology were associated
with cavitation, but adenocarcinomas cavitate as well, and
overall, there appeared to be no clinical significance to those
patients that developed cavitation during therapy as the fre-
quency of hemoptysis, progression-free survival, and overall
survival were not different between the patients that devel-
oped cavitation and those that did not. In fact, hemoptysis
was associated with tumor size and more commonly seen in
tumors abutting segmental vessels rather than main vessels.
To our knowledge, our report is the first to focus on the
development of tumor cavitation after treatment with antian-
giogenesis agents in patients with lung cancer.
Angiogenesis, or formation of new blood vessels, has
been the subject of intense research in recent years,5 and is
rapidly becoming an important evolving strategy in cancer
therapy.6 Of the antiangiogenesis agents, bevacizumab is the
most advanced in clinical research: it improved outcome in
renal-cell carcinoma7 and breast cancer,8 and is indicated for
first- or second-line treatment of carcinoma of the colon or
rectum.9,10 Recently, bevacizumab in combination with car-
boplatin and paclitaxel has shown to prolong survival and
time to progression of disease and to increase response rate in
NSCLC, and is now indicated for first-line treatment of
patients with unresectable, locally advanced, recurrent or
metastatic nonsquamous NSCLC.1 Other antiangiogenesis
agents that have shown beneficial clinical results are the
nonselective TKIs sorafenib11 and sunitinib,12 indicated in
patients with renal-cell carcinoma.
As these agents become part of common practice of
cancer therapy, a better understanding of their class-type
adverse events is essential. Indeed, hypertension, proteinuria,
and blood clots have been associated with antiangiogenesis
agents.6 In patients with lung cancer treated with bevacizumab,
hemoptysis is a serious and potentially fatal adverse event. In
nonselected lung cancer population, an association between
hemoptysis and squamous-cell histology was noted.2,13 How-
ever, hemoptysis was also documented in the NSCLC bevaci-
zumab phase III trial, which excluded squamous histology.1
An analysis presented at ASCO 2006 examined clinical and
radiographic characteristics of 425 bevacizumab treated lung
cancer patients. Ten cases of serious pulmonary hemorrhage
were identified. Of these, 7 were without additional compli-
cating factors, and 6 were of early-onset. Two of the two
patients with preexisting cavitation had bleeding.14 In addi-
tion, bevacizumab had been associated with organ perforation
(e.g., bowel or nasal) in patients with several solid malignan-
cies, including lung cancer.15,16 The exact pathologic mech-
anism leading to organ perforation is not clear. Formation
of tumor cavitation, which may be regarded as a similar
process, may have resulted from induction of central tumor
necrosis, as shown by preclinical models.2,17,18
Our study has several limitations. It is based on the
retrospective pooled analyses of 10 different trials, a strategy
that increases the studied population, but at the same time can
be seen as a potential limitation for the interpretation of the
findings. For example, some of the studies included and some
excluded histology of squamous-cell carcinoma. However,
such an approach is necessary to explore potential events that
may be related to the entire class of drugs, rather than result
from a single agent activity.
In conclusion, our retrospective study revealed that
tumor cavitation induced by antiangiogenesis agents in
NSCLC patients is common, seen in 16% of patients, which
may suggest a class effect. We did not find any association
between cavitation and any imaging characteristics of the
tumor, or hemoptysis. Cavitation did not have a significant
effect on the overall prognosis nor oncologic radiographic
results. Although hemoptysis correlated with tumor size and
segmental (i.e., peripheral) vasculature, the small number of
cases (n  5) was not sufficient to propose a clinical profile
of patients who are at a higher risk for bleeding. Further
research needs to address new ways to predict and prevent the
development of hemoptysis in patients under treatment with
antiangiogenesis agents, and reevaluate the possibility of
offering the benefit of this therapy to patients with central
tumors and/or squamous-cell histology.
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